8-K: Vivani Medical Q1 2026 Results: SLIM-1 Trial On Track, Cash Runway Extended

Vivani Medical reported first quarter 2026 financial results, highlighting the upcoming initiation of its Phase 1 SLIM-1 clinical trial for chronic weight management and a cash runway extending through the first half of 2027.

Summary

• Vivani Medical reported its first quarter 2026 financial results on May 13, 2026.
• The company is on track to initiate the SLIM-1 Phase 1 clinical trial for its semaglutide implant (NPM-139) for chronic weight management in mid-2026, with top-line results anticipated by the end of 2026.
• Vivani Medical has $28 million in cash, cash equivalents, restricted cash, and capital commitments, which are expected to fund operations through the first half of 2027.
• The company raised $30.2 million in gross proceeds over the last 12 months through various offerings.
• Plans are underway to transition its subsidiary, Cortigent Inc., into an independent, publicly traded company.
• Net loss for the first quarter of 2026 was $6.8 million, compared to $6.3 million in the first quarter of 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with key clinical trial milestones on track and an extended cash runway, balanced by an increased net loss and ongoing development costs.

Positives

• Initiation of the SLIM-1 Phase 1 clinical trial for NPM-139 (semaglutide implant) for chronic weight management is on track for mid-2026.
• Top-line results for the SLIM-1 trial are projected by the end of 2026.
• Cash, cash equivalents, and capital commitments of $28 million are expected to fund operations through the first half of 2027.
• Raised $30.2 million in gross proceeds over the last 12 months through share purchase agreements and registered direct offerings.
• Progress is being made on the next-generation NPM-139 implant configuration designed for higher doses of semaglutide.
• The company is exploring opportunities to realize value from its neuromodulation assets through Cortigent Inc.

Negatives

• Net loss for the first quarter of 2026 was $6.8 million, an increase from $6.3 million in the same period of 2025.
• Research and development expenses increased by 4% to $4.4 million in Q1 2026 from $4.2 million in Q1 2025.
• General and administrative expenses increased by 4% to $2.4 million in Q1 2026 from $2.3 million in Q1 2025.
• Other income, net, decreased significantly to $37,000 in Q1 2026 from $255,000 in Q1 2025.

Risks

• Risks related to developing subdermal implants and conducting clinical trials.
• Risks related to the biopharmaceutical industry generally.
• Risks associated with the Cortigent spin-off, including potential delays, failure to complete, or not achieving anticipated benefits.
• Unforeseen costs or delays in conducting business.
• Risks and uncertainties associated with the development and commercialization of products and product candidates.
• Potential for actual results to differ materially from forward-looking statements.

Future Outlook

Vivani Medical anticipates initiating its Phase 1 SLIM-1 clinical trial for NPM-139 in mid-2026, with top-line results expected by year-end. Pending positive results and FDA approval, a Phase 2 study is planned for 2027. The company also plans to transition its subsidiary, Cortigent Inc., into an independent, publicly traded entity.

Management Comments

• "Im very pleased with the progress our team made in the first quarter. We are on track to initiate the first study in our SLIM Clinical Program (Semaglutide ultra Long-acting IMplant in obesity). Our Phase 1 study of NPM-139, also known as SLIM-1, will be conducted in Australia and is anticipated to start mid-year 2026."
• "Based on our prior experience with the execution of our first-in-human LIBERATE-1 clinical trial in 2025, we anticipate top-line SLIM-1 results by the end of this year."
• "Our strong financial position, with a cash runway through the first half of 2027, underscores our ability to deliver on these milestones and drive meaningful progress in addressing critical healthcare needs."
• "As the obesity treatment landscape continues to evolve, challenges associated with medication adherence have emerged as a clear and undeniable barrier to the full realization of health outcomes otherwise possible with GLP-1 therapies."
• "With the potential to provide steady and continuous GLP-1 delivery over periods of 6 months, 12 months, or more, our NanoPortal technology is uniquely designed to solve for these challenges while still allowing for patients to stop exposure to the drug on a timeline similar to the current weekly injectables."

Industry Context

StockSavvy.ai notes that Vivani Medical's focus on ultra long-acting semaglutide implants addresses a critical unmet need in the rapidly growing obesity and diabetes treatment market, specifically targeting medication adherence challenges prevalent with current GLP-1 therapies. The company's strategy aligns with the industry trend towards innovative drug delivery systems that improve patient compliance and potentially enhance therapeutic outcomes.

Comparison to Industry Standards

• The initiation of a Phase 1 study for a novel drug delivery system like Vivani's semaglutide implant is a standard early-stage milestone in biopharmaceutical development.
• The projected cash runway through the first half of 2027 is a key metric for investors, indicating the company's ability to fund its near-term development plans, a common benchmark for early-stage biotech companies.
• The net loss of $6.8 million in Q1 2026 is typical for clinical-stage biopharmaceutical companies investing heavily in research and development, with comparisons often made to peers in similar development phases.
• The planned transition of Cortigent Inc. into an independent entity is a strategic move seen across the industry to unlock value in distinct business units, similar to spin-offs by larger pharmaceutical or medical device companies.

Legal Proceedings

• Litigation accrual of $1,675 thousand as of March 31, 2026, and December 31, 2025.

Related Party Transactions

• Proceeds from other securities purchase agreements with an affiliate of one of its independent directors and another investor contributed to financing activities in Q1 2026.

Stakeholder Impact

• Shareholders: Potential value realization from Cortigent spin-off, ongoing development progress of semaglutide implant.
• Patients: Potential for improved medication adherence and outcomes with long-acting semaglutide implants.
• Payors and Health Systems: Potential reduction in costs associated with non-adherence to GLP-1 therapies.

Next Steps

• Initiate the SLIM-1 Phase 1 clinical trial in mid-2026.
• Achieve top-line results for the SLIM-1 trial by the end of 2026.
• File an Investigational New Drug (IND) Application for NPM-139.
• Aim to launch a Phase 2 study in the SLIM program in 2027.
• Transition Cortigent Inc. into an independent, publicly traded company.

Key Dates

Recommendation

The company is making progress on key clinical development milestones and has a sufficient cash runway, but the increased net loss and the inherent risks in clinical-stage biopharmaceutical development warrant a cautious 'hold' recommendation pending further clinical data and regulatory progress.

Keywords

Vivani Medical, Semaglutide Implant, Chronic Weight Management, Clinical Trial, NPM-139, SLIM-1, Biopharmaceutical, GLP-1